Free Trial
NASDAQ:ELVN

Enliven Therapeutics Q4 2023 Earnings Report

Enliven Therapeutics logo
$16.02 +0.03 (+0.19%)
As of 03:56 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Enliven Therapeutics EPS Results

Actual EPS
-$0.47
Consensus EPS
-$0.56
Beat/Miss
Beat by +$0.09
One Year Ago EPS
N/A

Enliven Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Enliven Therapeutics Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Wednesday, March 13, 2024
Conference Call Time
7:00PM ET

Upcoming Earnings

Enliven Therapeutics' Q2 2025 earnings is scheduled for Tuesday, August 12, 2025, with a conference call scheduled on Friday, August 8, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Enliven Therapeutics Earnings Headlines

July 2025 Rule Change to Impact Retirement Investors
There's a massive change from a new rule going into effect this July. And it's one the Big Banks are already using to their advantage… It allows them to treat this new asset like actual cash.
What is HC Wainwright's Estimate for ELVN Q1 Earnings?
See More Enliven Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Enliven Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Enliven Therapeutics and other key companies, straight to your email.

About Enliven Therapeutics

Enliven Therapeutics (NASDAQ:ELVN), a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

View Enliven Therapeutics Profile

More Earnings Resources from MarketBeat